The Survey Research and Data Acquisition Resource (SRDAR) is a new CCSG Resource that originated out of the Cancer Prevention and Population Sciences Program in the summer of 2004. The mission of SRDAR is to provide a collaborative Resource within RPCI for data collection and study design services for investigators from CCSG Programs. Collecting valid and reliable survey data is critical for all investigators. SRDAR data collection services include phone surveys, face-to-face interviews, clinical followup assessments, trial recruitment, web-based surveys, mail-based biologic data collection, scannable forms and focus groups. SRDAR can also provide assistance with protocol development and dissemination of findings. The personnel structure includes the Resource Director, scientific coordinator, administrative coordinator, informatics coordinator and data collection staff (currently 30 FTE). Leading up to the designation as a CCSG Resource, RPCI contributed $167,520 in personnel and equipment expenses to create the SRDAR infrastructure. CCSG support will be used to defray these management expenses and chargebacks will cover 66% of the expected $1.1 million FY 2008 operating budget. Since its inception, SRDAR has supported 41 projects and generated $1.1 million in revenue;51% has come from peerreviewed sources, including 40% from NIH grants. As a CCSG Resource, SRDAR will seek to expand its role in research in all CCSG Programs. The Resource is used by two Programs and 88% of users are CCSG members. $98,966 in CCSG support is requested, representing 9% of the total operating budget.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016056-35
Application #
8296649
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2011-05-01
Budget End
2012-04-30
Support Year
35
Fiscal Year
2011
Total Cost
$225,600
Indirect Cost
Name
Roswell Park Cancer Institute Corp
Department
Type
DUNS #
824771034
City
Buffalo
State
NY
Country
United States
Zip Code
14263
Block, Matthew S; Vierkant, Robert A; Rambau, Peter F et al. (2018) MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. Mayo Clin Proc 93:307-320
Li, Qiuhui; Deng, Qu; Chao, Hsueh-Ping et al. (2018) Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses. Nat Commun 9:3600
Rossetti, Stefano; Wierzbicki, Andrzej J; Sacchi, Nicoletta (2018) Undermining ribosomal RNA transcription in both the nucleolus and mitochondrion: an offbeat approach to target MYC-driven cancer. Oncotarget 9:5016-5031
Mett, V; Komarova, E A; Greene, K et al. (2018) Mobilan: a recombinant adenovirus carrying Toll-like receptor 5 self-activating cassette for cancer immunotherapy. Oncogene 37:439-449
Long, Mark D; Singh, Prashant K; Russell, James R et al. (2018) The miR-96 and RAR? signaling axis governs androgen signaling and prostate cancer progression. Oncogene :
Kawaguchi, Tstutomu; Yan, Li; Qi, Qianya et al. (2018) Novel MicroRNA-Based Risk Score Identified by Integrated Analyses to Predict Metastasis and Poor Prognosis in Breast Cancer. Ann Surg Oncol 25:4037-4046
Vexler, Albert; Yu, Jihnhee; Zhao, Yang et al. (2018) Expected p-values in light of an ROC curve analysis applied to optimal multiple testing procedures. Stat Methods Med Res 27:3560-3576
Mussell, Ashley L; Denson, Kayla E; Shen, He et al. (2018) Loss of KIBRA function activates EGFR signaling by inducing AREG. Oncotarget 9:29975-29984
Hirose, Yuki; Nagahashi, Masayuki; Katsuta, Eriko et al. (2018) Generation of sphingosine-1-phosphate is enhanced in biliary tract cancer patients and is associated with lymphatic metastasis. Sci Rep 8:10814
Kesterson, Joshua P; Szender, J Brian; Schaefer, Eric et al. (2018) Evaluation of Association Between Gynecologic Oncology Fellowship Length and a Career in Academic Medicine. J Cancer Educ 33:141-146

Showing the most recent 10 out of 1555 publications